KRT9

Across TCGA pan-cancer cohorts, KRT9 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KRT9 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher KRT9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRT9 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

BLCA, STAD, and LUSC are the cancer types where KRT9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.018	0.684	<.001	24	view →
STAD	OS	Median	II,III,IV	0.501	0.677	<.001	22	view →
LUSC	DFS	Median	All	0.079	0.792	<.001	18	view →
LIHC	DFS	Median	All	0.100	0.557	<.001	9	view →
GBM	DFS	Median	All	1.000	0.194	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KRT9–BLCA (OS)

Open the BLCA breakdown →